

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 May 2019 (23.05.2019)



(10) International Publication Number
WO 2019/099897 A1

(51) International Patent Classification:

A61K 35/748 (2015.01) A61K 36/02 (2006.01)
A61K 35/74 (2015.01) A23L 33/105 (2016.01)
A61K 31/7052 (2006.01)

(21) International Application Number:

PCT/US2018/061613

(22) International Filing Date:

16 November 2018 (16.11.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/587,488 17 November 2017 (17.11.2017) US

(71) Applicant: **FAR EAST BIO-TEC CO., LTD.**; 13f, No.3,
Yuan Chiu Street, Nan-Gang District, Taipei City, 115
(TW).

(71) Applicant (for TG only): **GLOBOASIA LLC** [US/US];
11427 Potomac Oaks Drive, Rockville, MD 20850 (US).

(72) Inventors: **CHIUH, Chuang-Chun**; RM. A, 13f., No.3,
Park St., Nangang Dist., Taipei City, 115 (TW). **CHEN, Yi-
Hsiang**; RM. A, 13f., No.3, Park St., Nangang Dist., Taipei
City, 115 (TW). **WU, Ming-Shun**; 1F., No.36, Aly. 4, Ln.
12, Sec.3, Xinglong Rd., Wenshan Dist., Taipei City, 116
(TW). **CHEH, Chun-Wei**; RM. A, 13F., No.3, Park St.,
Nangang Dist., Taipei City, 115 (TW).

(74) Agent: **KING, Anthony**; WPAT, P.C., 1100 Quail Street,
Suite 202, Newport Beach, CA 92660 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(54) Title: USE OF CYANOBACTERIAL BIOMASS IN TREATING HEPATITIS B VIRUS INFECTION




FIG. 1

(57) Abstract: Disclosed herein is the use a cyanobacterial biomass for treating hepatitis B virus (HBV) infection, in particular, chronic HBV infection. According to various embodiments of the present disclosure, the cyanobacterial biomass, upon administration of at least one month, significantly reduces the level of the surface antigen of hepatitis B virus (HBsAg) detectable in the subject receiving the treatment and/or mitigates insomnia associated with chronic HBV infection.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))